Hovione Technology has partnered with Kiel University Institute of Pharmacy on methods of dry powder formulation for delivery of high doses of antibiotics using Hovione Technology TwinMax and 8Shot DPIs, the company said. Areas of exploration will include techniques such as the use of soft pellets and nanocrystals for formulation of drugs such as clarithromycin and rifampicin.
Both of the Hovione Technology large dose DPIs are disposable, single-use devices manufactured from only two plastic parts each. The TwinMax DPI can deliver two 50 mg doses and the 8Shot DPI eight 50 mg doses without a need for the patient to reload the device. The company’s other DPIs include the TwinCaps, the PowdAir, and the Papillon.
Hovione Technology Director of Technology Development and Licensing João Ventura Fernandes commented, “We are excited to collaborate with world leading researchers in the field of inhaled drug delivery and very pleased they decided to work with our large dose DPI technologies TwinMax and 8Shot. We are observing new drugs to treat cystic fibrosis, pulmonary arterial hypertension, idiopathic pulmonary fibrosis or lung infections are requiring delivery of large lung doses, often within the range of 50 to 150 mg.”
Kiel University’s Institute of Pharmacy Director Regina Scherließ said, “If we want to deliver high doses of drug to the lung, it is not only about an innovative formulation, but we also need an effective delivery device. Thus, we are very happy to include Hovione Technology’s large dose DPIs into our formulation research.”
Read the Hovione Technology press release.
